Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 18/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13882118 | 0.82 | EPHX2 (0.61) | DDR1EPHX2 | |
| SCHEMBL2906200 | 0.81 | EPHX2 (0.47) | PPARGEPHX2 | |
| SCHEMBL2901573 | 0.80 | EPHX2 (0.51) | PPARGEPHX2 | |
| SCHEMBL3032631 | 0.80 | EPHX2 (0.54) | DDR1EPHX2 | |
| Trifluoroacetic Acid SCHEMBL2901345 | 0.80 | EPHX2 (0.58) | DDR1EPHX2 | |
| SCHEMBL2906483 | 0.79 | LMNA (0.46) | DDR1EPHX2 | |
| SCHEMBL2904563 | 0.79 | EPHX2 (0.62) | EPHX2 | |
| SCHEMBL2904023 | 0.78 | EPHX2 (0.43) | DDR1EPHX2 | |
| SCHEMBL2903561 | 0.77 | EPHX2 (0.61) | DDR1EPHX2 | |
| SCHEMBL3470922 | 0.75 | EPHX2 (0.49) | PPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | DDR1 4476/4885PPARG 4031/4885EPHX2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.